Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVT-RS101
- Development stage
- Unknown
- Lead developer
- Laboratorios Salvat
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
SVT-RS101 is a drug candidate being developed by Laboratorios Salvat for the treatment of moderate to severe chronic dry eye disease. Laboratorios Salvat is a specialty pharmaceutical company that focuses on drug delivery technologies and the reformulation of known molecules. SVT-RS101 is designed for topical ophthalmic administration. While the specific active ingredient and mechanism of action have not been publicly disclosed, the drug is currently in the preclinical stage of development. The company frequently utilizes its proprietary IMPACT-SVT® nanoemulsion technology for its ophthalmic pipeline to improve the delivery and efficacy of topical treatments for ocular surface and retinal diseases.
Beyond the preview
Go deeper on SVT-RS101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SVT-RS101.